2022 Fiscal Year Final Research Report
Development of the novel liquid biopsy systems for diagnosing Alzheimer's disease
Project/Area Number |
20K20223
|
Research Category |
Grant-in-Aid for Early-Career Scientists
|
Allocation Type | Multi-year Fund |
Review Section |
Basic Section 90130:Medical systems-related
|
Research Institution | Kobe University |
Principal Investigator |
IHARA Kohei 神戸大学, バイオシグナル総合研究センター, 学術研究員 (10866106)
|
Project Period (FY) |
2020-04-01 – 2023-03-31
|
Keywords | リキッドバイオプシー / 診断 / シトクロムP450 / アルツハイマー病 / 神経変性疾患 |
Outline of Final Research Achievements |
Alzheimer’s disease (AD) is the most common neurodegenerative diseaseworldwide. Effective liquid biopsy methods and biomarkers for AD have not yet been established. Previously, we developed a cytochrome P450 inhibition assay which can detect alterations of metabolite levels associated with P450s caused by onset of some inflammation associated diseases. In recent year, it has been revealed that the pathology of AD is related to the function of P450s. However, it is unknown whether the P450 inhibition assay can be applicable to AD diagnosis. Here, we demonstrated whether the P450 inhibition assay can discriminate sera between patients with AD and healthy controls. The results of the assay revealed that P450 inhibition assay can discriminate AD with area under the receiver operating characteristic curve values 0.933 in humans. These results demonstrate that the P450 inhibition assay can aid in the future development of liquid biopsy-based diagnostic methods for AD.
|
Free Research Field |
生化学
|
Academic Significance and Societal Importance of the Research Achievements |
アルツハイマー病は認知症の原因として最も多い疾患であり、超高齢化社会を迎える日本や、世界の多くの国で問題となっている。これらの疾患を克服するためには、早期の診断と早期の治療介入が必要とされているが、自覚症状がほとんどない発症初期の患者に対する有効なスクリーニング検査は確立できておらず、アルツハイマー病の克服において重要な課題の一つになっている。本研究では、新規の診断技術P450蛍光阻害アッセイ法を用いて、アルツハイマー病やパーキンソン病などの神経変性疾患の診断への応用可能性を示すことができた。この新規技術は、神経変性疾患を克服するための一助になることが期待される。
|